NYSE:PFE - Pfizer Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$44.18 +0.67 (+1.54 %)
(As of 11/20/2018 02:40 AM ET)
Previous Close$43.51
Today's Range$43.51 - $44.27
52-Week Range$33.20 - $45.81
Volume22.20 million shs
Average Volume22.20 million shs
Market Capitalization$259.01 billion
P/E Ratio16.67
Dividend Yield3.15%
Beta0.88
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brands. This segment also engages in the research and development, as well as contract manufacturing activities. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; Immutep Limited; BioNTech AG; Neofluidics, LLC; Kite Pharma, Inc.; Merck KGaA; Leap Therapeutics, Inc.; and Nektar Therapeutics, as well as development agreement with Antares Pharma, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSE:PFE
Previous Symbol
CUSIP71708110
Phone212-733-2323

Debt

Debt-to-Equity Ratio0.47
Current Ratio1.43
Quick Ratio1.15

Price-To-Earnings

Trailing P/E Ratio16.67
Forward P/E Ratio14.73
P/E Growth2.19

Sales & Book Value

Annual Sales$52.55 billion
Price / Sales5.01
Cash Flow$3.8086 per share
Price / Cash11.60
Book Value$12.02 per share
Price / Book3.68

Profitability

EPS (Most Recent Fiscal Year)$2.65
Net Income$21.31 billion
Net Margins44.63%
Return on Equity25.26%
Return on Assets10.72%

Miscellaneous

Employees90,200
Outstanding Shares5,952,870,000
Market Cap$259.01 billion
OptionableOptionable

Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Thursday, September 27th. Investors of record on Friday, November 9th will be paid a dividend of $0.34 per share on Monday, December 3rd. This represents a $1.36 annualized dividend and a yield of 3.08%. The ex-dividend date is Thursday, November 8th. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer declared that its board has approved a stock buyback plan on Tuesday, December 19th 2017, which authorizes the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company's board of directors believes its stock is undervalued.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) released its quarterly earnings data on Tuesday, October, 30th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.75 by $0.03. The biopharmaceutical company had revenue of $13.30 billion for the quarter, compared to the consensus estimate of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. The firm's quarterly revenue was up 1.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.67 earnings per share. View Pfizer's Earnings History.

When is Pfizer's next earnings date?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, January 29th 2019. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY18 earnings guidance on Tuesday, October, 30th. The company provided earnings per share (EPS) guidance of $2.98-3.02 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.99. The company issued revenue guidance of $53-53.7 billion, compared to the consensus revenue estimate of $54.16 billion.

What price target have analysts set for PFE?

22 brokerages have issued 1-year price objectives for Pfizer's stock. Their forecasts range from $37.00 to $53.00. On average, they expect Pfizer's share price to reach $43.00 in the next twelve months. This suggests that the stock has a possible downside of 2.7%. View Analyst Price Targets for Pfizer.

What is the consensus analysts' recommendation for Pfizer?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 2 sell ratings, 13 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

What are Wall Street analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:
  • 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and raise our 12-month PT for PFE shares to $53 from $45. The increase in our PT is driven by multiple expansion. We think this is deserved because respectable earnings growth, driven by Innovative Medicines, recent pipeline advancements, and return of capital to PFE’s shareholders — above the industry average — are all still underappreciated." (10/17/2018)
  • 2. According to Zacks Investment Research, "Pfizer is facing top-line headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition. Nonetheless, we believe that new products like Ibrance, contribution from acquisitions, cost-cutting efforts, a lower tax rate and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals through 2022, including around 15 products that have blockbuster potential. Pfizer’s growing immuno-oncology portfolio has strong potential.  Bavencio is being considered a key long-term growth driver for Pfizer. In oncology, Pfizer has three potential medicines under FDA’s priority review. The stock has outperformed the industry this year so far. Estimates have remained stable ahead of its Q3 earnings release and Pfizer has a positive record of earnings surprises in recent quarters." (10/16/2018)

Has Pfizer been receiving favorable news coverage?

Media stories about PFE stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pfizer earned a daily sentiment score of 0.9 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.

Are investors shorting Pfizer?

Pfizer saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 46,551,071 shares, a decrease of 7.5% from the October 15th total of 50,351,438 shares. Based on an average trading volume of 26,087,863 shares, the short-interest ratio is presently 1.8 days. Approximately 0.8% of the company's stock are sold short. View Pfizer's Current Options Chain.

Who are some of Pfizer's key competitors?

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:
  • Mr. Ian C. Read, Chairman & CEO (Age 64)
  • Mr. Frank A. D'Amelio, CFO & EVP of Global Supply and Bus. Operations (Age 60)
  • Mr. Albert Bourla D.V.M., DVM, Ph.D., COO & Director (Age 56)
  • Dr. Mikael Dolsten, Global Pres of Worldwide R&D and Medical (Age 59)
  • Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 53)

Who are Pfizer's major shareholders?

Pfizer's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.57%), Capital World Investors (1.43%), Bank of New York Mellon Corp (1.18%), Massachusetts Financial Services Co. MA (1.01%), Dimensional Fund Advisors LP (0.90%) and Fisher Asset Management LLC (0.68%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

Which major investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Mitsubishi UFJ Trust & Banking Corp, Nordea Investment Management AB, BlackRock Inc., American Century Companies Inc., FMR LLC, The Manufacturers Life Insurance Company and Epoch Investment Partners Inc.. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

Which major investors are buying Pfizer stock?

PFE stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, AQR Capital Management LLC, Bessemer Group Inc., Bank of New York Mellon Corp, Canada Pension Plan Investment Board, Assenagon Asset Management S.A., Glenmede Trust Co. NA and Skandinaviska Enskilda Banken AB publ . View Insider Buying and Selling for Pfizer.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $44.18.

How big of a company is Pfizer?

Pfizer has a market capitalization of $259.01 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

What is Pfizer's official website?

The official website for Pfizer is http://www.pfizer.com.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.


MarketBeat Community Rating for Pfizer (NYSE PFE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,224 (Vote Outperform)
Underperform Votes:  683 (Vote Underperform)
Total Votes:  1,907
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2018 by MarketBeat.com Staff

Featured Article: What is Depreciation?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel